Scarlet Fever: Streptococcal Infection and Characteristic Rash

Overview of Scarlet Fever

Scarlet fever, also known as scarlatina, is an acute infection caused by Group A Streptococcus (GAS) producing erythrogenic toxins, resulting in a characteristic fine, sandpaper-textured rash. While historically a severe and sometimes fatal condition, modern scarlet fever is typically mild to moderate and responds well to antibiotics. The disease now occurs most commonly as a complication of streptococcal pharyngitis but can follow impetigo or streptococcal wound infections. The disease is highly contagious through respiratory droplets, spreading rapidly in school and daycare settings, particularly during late fall and winter months in temperate climates. Understanding the characteristic clinical presentation, potential complications, and appropriate antibiotic therapy is essential for pediatric practitioners, as untreated streptococcal infections carry risk of serious sequelae including acute rheumatic fever and glomerulonephritis.

Epidemiology and Streptococcal Virulence

Scarlet fever results from infection with Group A Streptococcus strains that produce streptococcal pyrogenic exotoxins (SPEs), including SPE A, SPE B, and SPE C. These toxins act as superantigens, stimulating massive T-cell proliferation and cytokine release, which triggers the characteristic rash and systemic symptoms. GAS is a Gram-positive, beta-hemolytic bacterium spread through respiratory droplets, with peak incidence in children 5-12 years of age. The incidence of scarlet fever has declined markedly from its early 20th-century prevalence, though cases continue to occur globally. Recent decades have seen re-emergence of scarlet fever in some geographic regions, particularly associated with invasive GAS strains. Transmission occurs through respiratory droplets, direct contact with infected wounds, or consumption of contaminated foods. Untreated patients are contagious for approximately 2 weeks; antibiotic therapy reduces this to 24-48 hours after treatment initiation.

Clinical Presentation and Rash Characteristics

Scarlet fever typically begins with acute onset of fever, sore throat, headache, malaise, and nausea or vomiting. The characteristic erythematous rash typically appears 12-48 hours after symptom onset, initially on the chest and neck before spreading to the trunk and extremities. The rash is distinctly different from typical streptococcal pharyngitis without toxin production. The exanthem consists of fine, punctate erythema giving the appearance and texture of sandpaper, distinguishing it from the maculopapular rashes seen in viral exanthems. The rash blanches with pressure and is non-pruritic to mildly pruritic. Characteristic features include pastia's lines (accentuated erythema in body folds) and sparing of the circumoral region, creating a classic "strawberry tongue" appearance with red, swollen papillae surrounded by white coating that later desquamates. Oropharyngeal involvement includes intense pharyngeal erythema, exudate, and enlargement of tonsils. The rash typically lasts 3-7 days and may be followed by fine desquamation, particularly on the palms and soles.

Systemic and Complicated Infections

While uncomplicated scarlet fever with appropriate treatment carries excellent prognosis, untreated streptococcal infection carries significant risk of serious complications. Acute rheumatic fever (ARF) occurs in 3-10% of untreated streptococcal pharyngitis cases and in a higher percentage when multiple episodes occur. ARF can result in permanent carditis with valvular damage, arthritis, chorea, subcutaneous nodules, and erythema marginatum. Post-streptococcal glomerulonephritis occurs in 10-15% of untreated streptococcal pyoderma cases and approximately 1-5% of untreated pharyngitis cases. Other complications include suppurative sequelae such as bacteremia, meningitis, septic arthritis, and necrotizing fasciitis, though these are relatively uncommon with modern management. Toxic shock syndrome has been reported with invasive GAS strains. Streptococcal toxic shock syndrome (STSS) is a life-threatening complication characterized by shock, multiorgan failure, and high mortality, though this is uncommon with adequate antibiotic therapy.

Diagnosis and Laboratory Findings

Diagnosis of scarlet fever is clinical based on the presentation of streptococcal pharyngitis with characteristic rash. A throat culture or rapid streptococcal antigen test from a throat swab confirms Group A Streptococcus infection. Rapid antigen tests have excellent specificity but variable sensitivity (80-95%) depending on technique and patient characteristics. Throat culture remains the gold standard, with results available within 24-48 hours. Rising antistreptolysin O (ASO) titers or anti-DNase B titers demonstrate recent streptococcal infection and can be useful in confirming infection retrospectively or when pharyngitis is complicated by post-streptococcal sequelae. Complete blood count may show elevated white blood cell count with left shift. Differential diagnosis includes viral exanthems (lack sandpaper texture and strawberry tongue), measles (cough and coryza typically more prominent), and other bacterial infections. The combination of streptococcal pharyngitis with characteristic sandpaper rash and strawberry tongue is diagnostic for scarlet fever.

Treatment and Prevention of Sequelae

Treatment of scarlet fever requires antibiotics to eliminate the streptococcal infection and prevent serious sequelae. Penicillin remains first-line therapy, with oral penicillin V 250 mg twice to three times daily for 10 days for children, or intramuscular penicillin G for those unable to take oral medication. Amoxicillin is commonly substituted with similar efficacy. For penicillin-allergic patients, first-generation cephalosporins (cephalexin) are effective alternatives in those without true IgE-mediated penicillin allergy. Macrolides such as azithromycin or erythromycin may be used but show increasing resistance rates. Treatment should be continued for the full 10-day course despite clinical improvement, as this duration is necessary to prevent acute rheumatic fever and other sequelae. Symptomatic management with antipyretics and analgesics provides comfort. Throat cultures should not be obtained immediately after treatment to confirm eradication, as bacterial colonization without disease can persist.

Frequently Asked Questions

Why does scarlet fever have a rash when strep throat doesn't? Scarlet fever results from GAS strains that produce erythrogenic toxins. These toxins cause the characteristic rash. Strep throat without toxin production lacks the rash.

Is scarlet fever dangerous today? Modern scarlet fever is typically mild and responds well to antibiotics. However, untreated streptococcal infection risks serious complications including rheumatic fever.

How long is my child contagious? Untreated patients are contagious for about 2 weeks. Antibiotic therapy reduces contagiousness to 24 hours after starting treatment.

Will the rash scar my child's skin? No. Scarlet fever rashes are superficial and resolve without scarring. Desquamation may occur but does not represent scarring.

Can scarlet fever recur? Yes, reinfection with different GAS strains can occur. Each episode carries risk of rheumatic fever if untreated.

References